The global blood plasma-derived products market has shown consistent growth over the period 2002-2009 and the rapid increase in cases of Hemophilia, low treatment cost to patients and rising ageing population are the major factors that will be driving the market for plasma-derived products in coming years.
Immunoglobulin (IVIG) and albumin account for the largest share of the global plasma market. The demand for blood albumin has increased over the years due to growing usage of albumin as a cell culture medium ingredient, antioxidant and also as the most effective volume expander in critical care conditions such as liver disease and hemorrhagic stroke. Another significant factor in albumin demand has been growing needs from emerging markets like China which has started importing albumin from Western companies. CSL and Baxter currently are the biggest plasma fractionation companies.
Factor VIII account for a major portion of plasma-derived clotting factor and lack of which causes Hemophilia A. Demand for genetically engineered recombinant Factor VIII (rFVIII) is also increasing as they carry less risk of carrying viral strains and plasma-borne diseases. Baxter has the largest market share in rFVIII market.
The present report offers an analysis of the global albumin and Factor VIII market with a special focus on country analysis like the US and China market. It also discusses key growth drivers and major challenges faced by the industry. The report also profiles major players in the albumin and Factor VIII market.
Further, we have predicted the future growth of albumin and Factor VIII market by combining SPSS data integration and analysis capabilities with our relevant findings. We employed various significant variables that have an impact on this industry and created regression models with SPSS to determine the future direction of the industry.
Make an enquiry before buying this Report
Please fill the enquiry form below.